Download PDF
Hamostaseologie 2016; 36(02): 103-107
DOI: 10.5482/HAMO-14-11-0063
Review
Schattauer GmbH

End-stage renal disease and thrombophilia

Nierenversagen und Thrombophilie
Alexander Bauer
1   Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, University Hospital Schleswig-Holstein, Campus Kiel & Lubbock, Germany
,
Verena Limperger
1   Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, University Hospital Schleswig-Holstein, Campus Kiel & Lubbock, Germany
,
Ulrike Nowak-Göttl
1   Institute of Clinical Chemistry, Thrombosis & Hemostasis Treatment Center, University Hospital Schleswig-Holstein, Campus Kiel & Lubbock, Germany
› Author Affiliations
Further Information

Publication History

received: 13 November 2014

accepted in revised form: 23 January 2015

Publication Date:
20 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die chronische Niereninsuffizienz (chronic kidney disease; CKD) stellt einen bekannten Risikofaktor für die Entwicklung einer arteriellen und venösen Thromboembolie (TE) dar. Das Risiko für eine TE ist bei moderat eingeschränkter Nierenfunktion ca. 2,5-fach erhöht und steigt mit zunehmender Insuffizienz auf etwa das 5,5-Fache. Vergleicht man Patienten mit einer chronischen Niereninsuffizienz mit Patienten, die zusätzlich folgende Risikofaktoren aufweisen, erhöht sich das TE-Risiko erheblich: CKD und arterielle Thrombose: OR 4.9, CKD und maligne Grunderkrankung: OR 5.8, CKD und chirurgischer Eingriff: OR14.0; CKD und angeborene Thrombophilie (OR 4.3).

Die Behandlung der terminalen Niereninsuffizienz besteht in Dialyse, Peritonaldialyse und Nierentransplantation. Bei allen Verfahren sind thromboembolische Komplikationen beschrieben. TEs, insbesondere aber Katheter-assoziierte Thrombosen oder Shuntverschlüsse treten in bis zu 25% der Dialysepatienten auf. Die Inzidenz einer Nierenvenenthrombose als Komplikation nach Nierentransplantation – verbunden mit hoher Wahrscheinlichkeit eines Organverlustes – wird mit 2–12% angegeben.

Da TE häufig multifaktoriell bedingt sind, erscheint ein generelles Screening auf Thrombophilie in diesem Patientenklientel nicht indiziert. Ein Screening sollte diskutiert werden bei Patienten, die entweder TEs vor Auftreten ihrer Nierenerkrankung entwickelt haben oder die eine positive Familienanamnese hinsichtlich VTE aufweisen. Auch Patienten, die unter Dialyse oder nach Transplantation multiple TEs erleiden und solche, die auf der Warteliste für eine Nierentransplantation (insbesondere Lebendspende) stehen, sollten hinsichtlich Thrombophilie untersucht werden.

Summary

Chronic kidney disease is an established risk factor for arterial and venous thromboembolism (TE). Whereas the overall risk of TE in moderately decreased kidney function is approximately 2.5-fold higher compared to patients with normal renal function, the risk increase is 5.5-fold in patients with severe renal dysfunction. In patients with renal dys-function and arterial thrombosis (OR: 4.9), malignancy (OR: 5.8) surgery (OR: 14.0) or thrombophilia (OR: 4.3) the risk to suffer from venous TE is higher compared to the risk associated to the baseline renal dysfunction alone.

The treatment options for end-stage renal diseases include hemodialysis, peritoneal dialysis and kidney transplantation. During all treatment modalities thrombotic complications have been described, namely catheter malfunction and shunt thrombosis in patients undergoing hemodialysis in up to 25% of patients, and TE, pulmonary embolism or graft vessel thrombosis in approximately 8% of patients. The reported incidence of reno-vascular thrombosis following renal transplantation leading to hemorrhagic infarction with organ rejection or organ loss varied between 2–12%.

Keeping in mind the multifactorial etiology of TE in patients with kidney dysfunction a general screening for thrombophilia in this patient group is not indicated. Selected screening on an individual patient basis should be discussed if the family history for TE is positive or the patient itself had suffered one thrombosis before the onset of the renal disease or multiple TEs during hemodialysis or post kidney transplantation in patients waiting for living donor kidney transplantation.

Schlüsselwörter

Chronisches Nierenversagen - Thrombose - Organ versagen - Thrombophilie

Keywords

Chronic kidney disease - thrombosis - organ failure - thrombophilia
 

  • References

  • 1 Kim WY, Huh JW, Lim CM. ET AL Analysis of progression in risk, injury, fail, loss and end-stage renal disease classification on outcome in patients with severe sepsis and septic shock. J Crit Care 2012; 27: 104e1-7.
    PubMedGoogle Scholar
  • 2 Rayane T, Haddoum E. Chronic renal failure in Algeria. Renal replacement therapy strategies and progression. Saudi Kidney Dis Transplant Bull 1993; 4 (Suppl. 01) 118.
    PubMedGoogle Scholar
  • 3 Kamoun A, Jawahdou F, Hachicha J. et al. Causes of end-stage chronic kidney failure in children in Tunisia. Arch Pediatr 1997; 4: 196-198.
    CrossrefPubMedGoogle Scholar
  • 4 Barsoum RS. End-stage renal disease in the developing world. Artif Organs 2002; 26: 735-736.
    CrossrefPubMedGoogle Scholar
  • 5 Schwab SJ, Harrington JT, Singh A. et al. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-2090.
    CrossrefPubMedGoogle Scholar
  • 6 Danis R, Ozmen S, Akin D. et al. Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis. J Thromb Thrombolysis 2009; 27: 307-315.
    CrossrefPubMedGoogle Scholar
  • 7 Allen RDM, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137-142.
    PubMedGoogle Scholar
  • 8 Humar A, Johnson EM, Gillingham KJ. Venous thromboembolic complications after kidney and kidney pancreas transplantation. Transplantation 1998; 65: 229-234.
    PubMedGoogle Scholar
  • 9 Torry RJ, Labarrere CA, Gargiulo P, Faulk WP. Natural anticoagulant and fibrinolytic pathways in renal allograft failure. Transplantation 1994; 58: 926-931.
    CrossrefPubMedGoogle Scholar
  • 10 Irish A. Renal allograft thrombosis: can thrombophilia explain the inexplicable?. Nephrol Dial Transplant 1999; 14: 2297-2303.
    CrossrefPubMedGoogle Scholar
  • 11 Boots JM, Christiaans MH, Van Duijnhoven EM. et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709.
    PubMedGoogle Scholar
  • 12 Bell DD, Rosental JJ. Arteriovenous graft life in chronic hemodialysis. A need for prolongation. Arch Surg 1988; 123: 1169-1172.
    CrossrefPubMedGoogle Scholar
  • 13 Fischereder M, 1 Göhring P, Schneeberger H. et al. Early loss of renal transplants in patients with thrombophilia. Transplantation 1998; 65: 936-939.
    CrossrefPubMedGoogle Scholar
  • 14 Andrassy J, Zeier M, Andrassy K. Do we need screening for thrombophilia prior to kidney transplantation?. Nephrol Dial Transplant 2004; 19 (Suppl. 04) iv64-iv68.
    PubMedGoogle Scholar
  • 15 Friedman GS, Meier-Kriesche HU, Kaplan B. et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72: 1073-1078.
    CrossrefPubMedGoogle Scholar
  • 16 Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal transplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1997; 63: 1263-1267.
    CrossrefPubMedGoogle Scholar
  • 17 Nampoory MR, Das KC, Johny KV. et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003; 42: 797-805.
    CrossrefPubMedGoogle Scholar
  • 18 O’Shea SI, Lawson JH, Reddan D. et al. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003; 38: 541-548.
    CrossrefPubMedGoogle Scholar
  • 19 Fukasawa M, Matsushita K, Kamiyama M. et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41: 637-642.
    CrossrefPubMedGoogle Scholar
  • 20 Ataç B, Yakupoğlu U, Ozbek N. et al. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc 2002; 34: 2030-2032.
    CrossrefPubMedGoogle Scholar
  • 21 Shemin D, 1 Lapane KL, Bausserman L. et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 1095-1099.
    PubMedGoogle Scholar
  • 22 Hernández E, Praga M, Alamo C. et al. Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. Nephron 1996; 72: 145-149.
    CrossrefPubMedGoogle Scholar
  • 23 Valeri A, Joseph R. Radhakrishnan A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. J Clin Nephrol 1999; 51: 116-121.
    PubMedGoogle Scholar
  • 24 LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999; 189: 73-81.
    CrossrefPubMedGoogle Scholar
  • 25 Knoll GA, Wells PS, Young D. et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005; 16: 1108-1114.
    CrossrefPubMedGoogle Scholar
  • 26 Klamroth R, Orlovic M, Fritsche I. et al. The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation. VASA 2013; 42: 32-39.
    PubMedGoogle Scholar
  • 27 Salmela B, Hartman J, Peltonen S. et al. Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol 2013; 8: 9628.
    PubMedGoogle Scholar
  • 28 Palomo I, Pereira J, Alarcón M. et al. Vascular access thrombosis is not related to presence of anti-phospholipid antibodies in patients on chronic hemodialysis. Nephron 2002; 92: 957-958.
    CrossrefPubMedGoogle Scholar
  • 29 Hojs R, Gorenjak M, Ekart R. et al. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 2002; 24: 215-222.
    CrossrefPubMedGoogle Scholar
  • 30 Adler S, Szczech L, Qureshi A. et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001; 56: 428-434.
    PubMedGoogle Scholar
  • 31 Födinger M, Mannhalter C, Pabinger I. et al. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Tranansplant 1996; 11: 668-672.
    PubMedGoogle Scholar
  • 32 Meyer M, Laux G, Scherer S. et al. No association of factor V Leiden, prothrombin G20210A, and MTHFR C677T gene polymorphisms with kidney allograft survival: a multicenter study. Transplantation 2007; 83: 1055-1058.
    CrossrefPubMedGoogle Scholar
  • 33 Ocak G, Lijfering WM, Verduijn M. et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. J Thromb Haemost 2013; 11: 627-633.
    CrossrefPubMedGoogle Scholar
  • 34 Takemoto S, Terasaki PI, Cecka JM. et al. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med 1992; 327: 834-839.
    CrossrefPubMedGoogle Scholar
  • 35 Lim WH, Clayton P, Wong G. et al. Outcomes of kidney transplantation from older living donors. Transplantation 2013; 95: 106-113.
    CrossrefPubMedGoogle Scholar
  • 36 Kute VB, Vanikar AV, Shah PR. et al. Outcome of living and deceased donor renal transplantation in patients aged >55 years: A single-center experience. Indian J Nephrol 2014; 24: 9-14.
    CrossrefPubMedGoogle Scholar
  • 37 Tasaki M, Saito K, Nakagawa Y. et al. 20-year analysis of kidney transplantation: a single center in Japan. Transplant Proc 2014; 46: 437-441.
    CrossrefPubMedGoogle Scholar
  • 38 Aktas S, Boyvat F, Sevmis S. et al. Analysis of vascular complications after renal transplantation. Transplantation Proc 2011; 43: 557-561.
    CrossrefPubMedGoogle Scholar
  • 39 Gruber SA, Chavers B, Payne WD. et al. Allograft renal vascular thrombosis--lack of increase with cyclosporine immunosuppression. Transplantation 1989; 47: 475-478.
    CrossrefPubMedGoogle Scholar
  • 40 Heidenreich S, Dercken C, August C. et al. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998; 9: 1309-1313.
    PubMedGoogle Scholar
  • 41 Hocher B, Slowinski T, Hauser I. et al. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2002; 87: 194-198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Heidenreich S, Junker J, Wolters H. et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospektive study. J Am Soc Nephrol 2003; 14: 234-249.
    CrossrefPubMedGoogle Scholar
  • 43 Jacquet A, Pallet N, Kessler M. et al. Outcome of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transplant Int 2011; 24: 582-587.
    CrossrefPubMedGoogle Scholar
  • 44 Su Z, Wang X, Gao X. et al. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. I Intern Med 2014; 276: 470-485.
    PubMedGoogle Scholar
  • 45 Koester BH, Köveker GB, Pötzsch B. et al. Hereditäre Thrombophilie als Ursache rezidivierender Transplantatthrombosen. Chirurg 1993; 64: 809-812.
    PubMedGoogle Scholar
  • 46 Oh J, Schaefer F, Veldmann A. et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999; 68: 575-578.
    CrossrefPubMedGoogle Scholar
  • 47 Fischereder M, Schneeberger H, Lohse P. et al. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38: 1061-1064.
    CrossrefPubMedGoogle Scholar
  • 48 Ghisdal L, Broders N, Wissing KM. et al. Thrombophilic factors do not predict outcomes in renal transplant recipients under prophylactic acetylsalicylic acid. Am J Transplant 2010; 10: 99-105.
    CrossrefPubMedGoogle Scholar
  • 49 Ghisdal L, Broeders N, Wissing KM. et al. Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrol Dial Transplant 2011; 26: 2700-2750.
    CrossrefPubMedGoogle Scholar
  • 50 De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. Thromb Haemost 2013; 110: 697-705.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 KDIGO Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-155.
    PubMedGoogle Scholar